Bipolar Disorder – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of bipolar disorder (BPD) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan). We report the prevalence of BPD for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.
Clarivate Epidemiology’s BPD forecast will answer the following questions:
- How will improvements in survival change the number of people living with a diagnosis of BPD?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of BPD over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
Clarivate Epidemiology provides at least 10 years of forecast data for the following BPD patient populations:
- Total lifetime prevalent cases of BPD.
- Total lifetime prevalent cases of BPD I.
- Total lifetime prevalent cases of BPD II.
- Diagnosed lifetime prevalent cases.
- Diagnosed drug-treated lifetime prevalent cases.
Note: Coverage may vary by country and region.
